Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177 Lu-DOTATATE treatment of NET patients.

Anna SundlövKatarina Sjögreen GleisnerJan TennvallMichael LjungbergCarl Fredrik WarfvingeKajsa HolgerssonAndreas HallqvistPeter BernhardtJohanna Svensson

Published in: European journal of nuclear medicine and molecular imaging (2022)

EudraCT 2011-000,240-16. NCT01456078. https://clinicaltrials.gov/ct2/show/NCT01456078.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
computed tomography
prognostic factors
peritoneal dialysis
pet ct
clinical trial
open label
contrast enhanced
image quality
patient reported outcomes
combination therapy
smoking cessation